Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life
暂无分享,去创建一个
André Thevenon | Arnaud Lacour | Vincent Tiffreau | Patrick Vermersch | Olivier Outteryck | P. Vermersch | É. Allart | A. Thevenon | V. Tiffreau | H. Zéphir | O. Outteryck | A. Lacour | Etienne Allart | Anne Benoit | Anne Blanchard-Dauphin | Hélène Zephir | A. Blanchard-Dauphin | Anne Benoit
[1] P. Feys,et al. Comparison of the 2- and 6-minute walk test in multiple sclerosis , 2011, Multiple sclerosis.
[2] N. Larocca,et al. Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus , 2016 .
[3] A. Vincent,et al. Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function , 2013, Drugs in R&D.
[4] Alessandra Solari,et al. The multiple sclerosis functional composite: different practice effects in the three test components , 2005, Journal of the Neurological Sciences.
[5] A. Achiron,et al. Gait analysis in multiple sclerosis: characterization of temporal-spatial parameters using GAITRite functional ambulation system. , 2009, Gait & posture.
[6] A. Cross,et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study , 2007, Multiple sclerosis.
[7] L. Krupp,et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis , 2008, Neurology.
[8] Ilse Lamers,et al. Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance , 2013, Multiple sclerosis.
[9] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[10] G. Moonen,et al. Motor Fatigue Measurement by Distance-Induced Slow Down of Walking Speed in Multiple Sclerosis , 2012, PloS one.
[11] J. Ware,et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.
[12] T. Berger,et al. Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases , 2013, Patient related outcome measures.
[13] Diana M Sobieraj,et al. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis , 2012, Current medical research and opinion.
[14] H. Wiendl,et al. Long-term effects of dalfampridine in patients with multiple sclerosis , 2014, Journal of the Neurological Sciences.
[15] F. Bethoux,et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials , 2015, Multiple sclerosis.
[16] R. Kaji,et al. Effects of 4‐aminopyridine in experimental CNS demyelination , 1988, Neurology.
[17] Deborah M. Miller,et al. Quality of Life in Multiple Sclerosis: Determinants, Measurement, and Use in Clinical Practice , 2010, Current neurology and neuroscience reports.
[18] S. Reingold,et al. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.
[19] L. Krupp,et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.
[20] N. Larocca,et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.
[21] A J Thompson,et al. Measuring the impact of MS on walking ability , 2003, Neurology.
[22] L. Krupp,et al. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. , 2006, Multiple sclerosis.
[23] S. Bowman,et al. The assessment of fatigue in primary Sjögren's syndrome , 2003, Scandinavian journal of rheumatology.
[24] G Giovannoni,et al. Multiple sclerosis related fatigue , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[25] U. Dalgas,et al. Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment , 2014, Multiple sclerosis.
[26] D. Goodkin,et al. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.
[27] J. Fischer,et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. , 2001, Archives of neurology.
[28] George C. Ebers,et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.
[29] L. Krupp,et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis , 2010, Annals of neurology.